Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

Part of paid clinical trials in Los Angeles, California.

Sponsor
Tubulis GmbH
Study ID
NCT07736937
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TUB-040 + Carbo + BEV — DRUG
    Ph1b: A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered along with carboplatin (Carbo) and bevacizumab (BEV) as an intravenous (IV) solution on day 1 of each treatment cycle for up to 6 cycles.

Study Details

The goal of this clinical study is to learn more about the safety, tolerability, and preliminary effectiveness of TUB-040 when given in combination with standard ovarian cancer treatments in participants with high-grade epithelial serous or endometrioid ovarian cancer. This study will also evaluate the appropriate dose of TUB-040 when used with carboplatin (Carbo) and bevacizumab (BEV), including determining the maximum tolerated dose (MTD) in participants with platinum-sensitive ovarian cancer.

Key Dates

First listed
Jul 30, 2026
Start date
Mar 30, 2026
Status verified
Aug 2026
Primary completion
Mar 31, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
72 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1b Dose Escalation
    Drug TUB-040 administered in combination with carboplatin (Carbo) and bevacizumab (BEV)

Primary Outcome Measure

To determine the safety and tolerability of TUB-040 in combination with standard ovarian cancer drugs [ Time Frame: From enrollment until 30 days after last study drug ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Start CalLos AngelesCalifornia90025-
Start NjebEast BrunswickNew Jersey08816-
Start NyliNew YorkNew York11042-

Find similar trials in Los Angeles, CA

Nationwide
Ovarian cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials
By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Start Cal· Los Angeles, CAStart Njeb· East Brunswick, NJStart Nyli· New York, NY

Related Studies